Drug: |
||||
---|---|---|---|---|
Trial Name: |
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 06/01/2008 |
Age of Trial (yrs) 15.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
CAMN107DIL02 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Basel |
|||
Contact email: |
||||
Contact Phone: |
41 61 324 1111 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Trial Links |
Trial Results |
Name |
Address |
City |
State |
Zip |
Country |
Tel Aviv |
Israel |
||||
Tel Hashomer |
Israel |
||||
Jerusalem |
Israel |